When a pharmaceutical company has positive data they don’t sit on it, they press release the top line data right away. They have had plenty of time since the completion of the study to get the data ready, we should be hearing about it any week now if it is positive. Everyday that passes increases the likelihood that the study has failed. I think it’s likely that it has failed unfortunately. It has been months now since the primary completion of the study has happened.
Samumed Sm04554 Results Normalized To Baseline
- Thread starter hypetraintime
- Start date
When a pharmaceutical company has positive data they don’t sit on it, they press release the top line data right away. They have had plenty of time since the completion of the study to get the data ready, we should be hearing about it any week now if it is positive. Everyday that passes increases the likelihood that the study has failed. I think it’s likely that it has failed unfortunately. It has been months now since the primary completion of the study has happened.
Yup that's usually the case. Only reason I'm not fully in agreement on this one is because covid might have caused some problems with data collection and overall study results and it might be causing them problems with putting it together.
Think about any people who got covid last year and might have had to stop the treatment, missed touch point visits, etc.
they would have amended the protocol to allow more people to join the study if that was the case, which would have changed the completion date of the study. The smoking gun is that they have updated the study clinicaltrials.gov to completed in January. Even with a 1 month follow up period, they have had this data for multiple months now.
Pharma companies are crack heads for positive press releases, especially with how hot the market has been. I highly doubt they are sitting on great news. This drug would be NDA ready and would be a meaningful source of income for the company. My guess is at best they have gotten mediocre/confusing data from this study, and they are trying to figure out a way to spin it as a positive.
Certainly seems this way, but it's a not a public company so we shall see.
That’s a fair point I did not know they were private. I still think news is imminent if the study was positive. We shall see.
- Reaction score
- 3
We are all in it together guys, I hope as much as you all that it’s positive but when you’ve been let down many times by misinformation and over hyped products that eventually fail it’s exhausting
Ouch, thanks for trying it and share your experience.
the problem I didn't even notice any result, the previous study has a good result which makes me think that the story that they are faking their stuff is true. i'm almost at 0.5g ( almost 5 months) of SM, not a single smell of improvement
Yes, the pharma company doing structured trials with a pure substance that they themselves had manufactured and rigorously tested is faking their stuff. Certainly wouldn't be the person with grey market sourced chemicals.
Depending on where you are with your loss, you probably wouldn't be able to notice a 10% improvement even if you achieved one.
- Reaction score
- 70
Samumed is now Biosplice, they received 120m in funding and male pattern baldness is still on the homepage but there is no mention in the press release:
So I'm not getting my hopes up..
So I'm not getting my hopes up..
- Reaction score
- 188
Wait what? This company rebranded itself and changed it's entire mission/target area with no press release? Uhhh
@pegasus2 You win this one. Even if the drug has clinically significant results this move is nothing but incredibly shady
Nothing actually changes with the drug obviously, but the argument against this company was that it was incredibly shady. This is an incredibly shady way to pivot the company, that press release doesn't even say why they changed names/direction or that they used to be Samumed. You can't find "Samumed" anywhere in that release. They also mention their entire pipeline except SM04554, which is closest to market. If it was about to drop impressive study results would be 100% listed there.
If I was an analyst covering private companies and I was following Samumed, this would be the largest red flag possible. There is nothing wrong with the name change in itself, but when companies are pivoting and don't do it in a PR friendly manor it's almost always a sign of large scale failures that they are hoping you don't notice.
Also, shifting to mRNA right as the hype is centered around this new emerging medical direction is the same thing as kodak camera's adding "blockchain" to their name and their stock going up 1000% overnight. It's a branding move in reaction to trying to generate investment.
No cope here, I thought the top-line data would have been out a month or two ago. Longer it went the more it was obvious. This move basically seals the deal.